Drugs / PEEL-224
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05329103 | Jul 2022 → Oct 2026 expected | neoplasm | Peel Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06721689 | Mar 2025 → Apr 2030 expected | neuroblastoma, refractory malignant neoplasm, rhabdomyosarcoma | Theodore Laetsch | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06709495 | Jan 2025 → Nov 2028 expected | Ewing sarcoma, desmoplastic small round cell tumor, osteosarcoma, rhabdomyosarcoma | David S Shulman, MD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEEL-224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05329103 ↗ |
| Known as | PEG-\[SN22\]4 | “PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor” NCT06721689 ↗ |
| Action | Inhibit | “a novel topoisomerase I inhibitor (PEEL-224)” NCT05329103 ↗ |
| Route | Intravenous | “PEEL-224 is administered intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle” NCT05329103 ↗ |